Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

20-Oct-2008 - Cell Genesys, Inc. announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer. The trial was fully enrolled in 2007 with 626 patients and compared GVAX immunotherapy to Taxotere(R) ...

Cell Genesys Provides Update on Clinical Program for GVAX Immunotherapy for Leukemia

Three New Clinical Trials Under Way

11-May-2007 - Cell Genesys, Inc. reported that three new clinical trials for GVAX immunotherapy for leukemia are now under way in collaboration with the Johns Hopkins Sidney Kimmel Cancer Center. The new trials are based on encouraging results in an initial Phase 2 study of the product in patients with chronic ...

CellGenesys Reports Encouraging Follow-Up Survival Data From Second Phase 2 Trialof GVAX Immunotherapy for Prostate Cancer

28-Feb-2006 - Cell Genesys, Inc. reported updated results from itssecond multi-center Phase 2 trial of GVAX(R) immunotherapy for prostate cancerin patients with advanced metastatic hormone-refractory prostate cancer (HRPC). Additional follow-up of thepatients who received the dose that is comparable to ...

CellGenesys Reports Positive Results From Phase 2 Trial of GVAX(R) Vaccine for Leukemia in Chronic Myelogenous Leukemia

VaccineReduces Molecular Evidence of Persistent Leukemia After Long-Term Gleevec(R) Therapy

14-Dec-2005 - Cell Genesys, Inc.reported encouraging clinical data from a Phase 2 trial ofGVAX(R) vaccine for chronic myelogenous leukemia (CML). Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year ofGleevec(R) (imatinib mesylate) therapy were treated with GVAX ...

Cell Genesys San Diego Manufacturing Operation Acquired by Genzyme

24-Nov-2005 - Cell Genesys, Inc. and Genzyme Corp. announced that Genzyme has acquired Cell Genesys' manufacturing operation in San Diego, CA to support the growth of Genzyme's gene therapy programs. Under the terms of the agreement, Genzyme will pay Cell Genesys $3.2 million in cash for the assets contained ...

Cell Genesys Reports Clinical Data From GVAX® Vaccine For Lung Cancer Program

06-Jul-2005 - Cell Genesys, Inc. reported data from a Phase 2 clinical trial of GVAX® vaccine for lung cancer, a patient-specific vaccine for patients with advanced-stage, non small-cell lung cancer (NSCLC). The trial, which is the second Phase 2 trial in this indication, enrolled 101 patients who were ...

Cell Genesys Reports Potential Breakthrough in Antibody Production Technology

22-Apr-2005 - Cell Genesys, Inc. scientists reported the development of a proprietary gene expression technology that enables the production of full-length monoclonal antibodies at commercially relevant levels from a single production cell line. Moreover, the time required to develop cell lines that can be ...

Cell Genesys Announces Management Changes

15-Mar-2005 - Cell Genesys, Inc. announced that Dr. Robert J. Dow has joined the company in the newly created position of senior vice president, medical affairs. The company also announced that Matthew J. Pfeffer, vice president and chief financial officer, intends to resign to spend more time with his family ...

Cell Genesys Reports Fourth Quarter and Full Year 2004 Results

27-Jan-2005 - Cell Genesys, Inc. reported a net loss for the quarter ended December 31, 2004 of $26.5 million, or $0.59 per share, and a net loss for the year then ended of $97.5 million, or $2.23 per share. This compares with a net loss of $17.3 million and a net loss of $56.6 million in the same quarter and ...

Cell Genesys Confirms Publication of Scientific Paper on GVAX(R) Lung Cancer Vaccine

23-Feb-2004 - Cell Genesys, Inc. confirmed that a press release issued by Baylor University concerned data from the initial Phase 1/2 clinical trial of Cell Genesys' GVAX® lung cancer vaccine trial. The data, which were published in the February 18, 2004 issue of the Journal of the National Cancer Institute, ...